1. Introduction {#sec1}
===============

In decades, it has been shown that steroids are important in many brain processes. In 1981, Baulieu and colleagues studied the steroid dehydroepiandrosterone sulfate, and concluded that the brain was a steroidogenic organ ([@bib46]). This led to the term 'neurosteroid', which is used to describe the subclass of steroids that are synthesized in the central nervous system ([@bib16]). A few years later, in 1986, Majewska and cols. found that the neurosteroid (NS) allopregnanolone (AlloP) acted as a positive allosteric modulator of γ-aminobutyric acid type A (GABAA) receptors ([@bib114]). This last discovery led to the term 'neuroactive steroids' (NS), which is used to describe all those steroids that, whether they are synthesized in the brain, the adrenal gland or gonads, are capable of modifying neuronal activity via membrane receptors modulation ([@bib63]; [@bib148]). The discovery of steroids that not only act as endocrine messengers but also in a paracrine or autocrine manner, and their capacity to rapidly modulate neural excitability, revealed that they are extremely important, given the huge array of brain activities in which they may be involved. Thus, in recent years, NS have been reported to participate in several brain processes and changes in their physiological levels have been related to a variety of neurological/psychiatric disorders and pathologic behaviors. It has also been shown that administering NS is beneficial in a number of experimental models of certain disorders (see [@bib63]; [@bib124]; [@bib154] for reviews).

NS levels in the brain are not static but rather naturally fluctuate over the life-time in response to different physiological and environmental conditions. For example, the concentration of AlloP oscillates during development ([@bib86]), the menstrual cycle ([@bib131]), pregnancy and post-partum ([@bib43]), as well as faster changes occur in response to adverse events, such as stress ([@bib156]; [@bib166]), or drugs, such as the systemic administration of alcohol ([@bib5]; [@bib44], [@bib45]). Surprisingly, although the actions of NS in the adult brain have been studied extensively, their role in the developing brain and their long-term effects are still poorly understood. The enzymes responsible for steroidogenesis are present in the brains of rats from early fetal stages ([@bib42]; [@bib106]; [@bib107]) and the ability of the fetal brain to synthesize NS has been proven ([@bib153]). Furthermore, pre and postnatal fluctuations of AlloP in the frontal cortex of rats are time-related to significant changes in brain development ([@bib86]). Thus, studying the involvement of NS, such as AlloP, in brain development and the possible effects of changes in their levels on vulnerability to neurological/psychiatric disorders is of great interest.

2. Neonatal allopregnanolone levels and stress {#sec2}
==============================================

GABAergic inhibitory control plays an important role in regulation hypothalamic-pituitary-adrenal (HPA) axis activation (see [@bib87] for a review). Several studies have shown that the GABAergic transmission rapidly decreases ([@bib25]; [@bib43]) while AlloP brain and plasma levels increase ([@bib7]; [@bib156]) in adult rats after acute stress, such as the exposure to CO2 or swimming. Moreover, this increase in AlloP levels correlates with the restoration of the GABAergic transmission ([@bib6]). Therefore, it has been suggested that endogenous AlloP represents a homeostatic mechanism in the context of adaptation to stress by limiting the extent and duration of the reduction in GABAergic inhibitory transmission and activation of the HPA axis ([@bib82]). In this line, it has been observed in humans that a pretreatment with 50 mg of progesterone prior to psychosocial stress diminished stress-induced cortisol increase ([@bib40]), showing the possible action of progesterone-derived metabolites, such as AlloP, on the HPA axis. However, it has been reported that chronic stress due to social isolation induces large reductions in AlloP cerebrocortical and plasma concentrations ([@bib166]), as well as alterations in brain NS levels, such as AlloP or tetrahydrodeoxycorticosterone (THDOC), in response to acute stressors. Thus, it has been proposed that a disruption in this homeostatic mechanism may play a pathogenic role in some psychiatric disorders related to chronic stress, for instance, depressive disorders ([@bib82]). Therefore, the administration of exogenous AlloP either during or following a period of chronic stress, such as social isolation, can prevent or normalize HPA axis dysfunction, precluding the establishment of depressive/anxiety-like behaviors in the rat ([@bib67]). On the other hand, it seems that there are some individuals more sensitive to these NS levels fluctuations. In this sense, it has been observed that NS level changes are relevant to the induction of the altered affective state in women with premenstrual dysphoric disorder (for a review see [@bib178]), which are more vulnerable to increased anxiety ([@bib102]) and alcohol abuse ([@bib169]; [@bib35]; [@bib41]).The possibility that these women have suffered NS levels alterations during neurodevelopment that could have made them more behaviorally sensitive to these fluctuations in adulthood is a question that opens new lines of research.

During the perinatal period the brain is highly sensitive to environmental factors, and thus early exposure to adverse experiences like stress have been related to several developmental alterations, such as impoverished dendritic trees and reduced hippocampal volume, and adult disorders, such as long-lasting memory deficits (see [@bib4]; [@bib30]; [@bib39] for a review). In neonatal animals, early stress arises mainly from disruptions in maternal care. For this reason, several models of neonatal stress in rodents consist in manipulating maternal-pup interactions. One of the main methods used to cause stress for the pups which has consequences for their cognitive and emotional networks and functional outcomes, is early maternal separation (EMS) ([@bib39]), in its many procedure variants (see [@bib80] for a review).

Changes in AlloP levels related to stress have also been observed during early postnatal stages ([@bib79]; [@bib99]). Given that adequate inhibitory GABAergic control is necessary for stress regulation, variations in physiological AlloP levels may imply changes in stress responses, and thus different outcomes of neonatal stress. Previous works studying the effects of administering AlloP on neonatal stress have shown that administering AlloP prior to a brief EMS at postnatal day 7 decreased the ultrasonic vocalizations of rats ([@bib183]; [@bib185]). Ultrasonic vocalizations are emitted by neonatal rat pups in the range of 20--50 kHz and are thought to contribute to the formation of the maternal-infant bond as infant mammals vocalize when separated from their mothers to elicit protection, nourishment and warmth ([@bib185]). Therefore, the analysis of ultrasonic vocalizations is used to measure the pup\'s affective state ([@bib184]). Other authors have shown that when the neurosteroid THDOC, which is a GABAA-positive modulator, is administered together with EMS, it can attenuate the adult behavioral and neuroendocrine consequences of this repeated stress during early life (i.e. increased anxiety, enhanced HPA axis responses to stress, such as an exaggerated adrenocortical secretion, and impaired glucocorticoid feedback). ([@bib147]). Similarly, a single administration of 2 mg/kg of AlloP injected just prior to 12h of EMS on postnatal day 5 counteracted the increased HPA axis response to subsequent stressors in both infants and adult rats ([@bib126]). Thus, administering NS, such as AlloP, which acts as a positive modulator of GABAA receptors, might prevent or reverse some of the negative neuroendocrine and behavioral effects of neonatal stress. In fact, it has been suggested that a transient increase in NS biosynthesis may contribute to the stress hypo-responsive period (SHRP) ([@bib126]). The early postnatal period between postnatal days 2 and 14 is known as SHRP and is a phase of high plasticity within the CNS with neuronal migration, synaptogenesis and apoptosis ([@bib87]). During this period, animals have low corticosterone (CORT) and adrenocorticotropic hormone (ACTH) levels in response to stress ([@bib162]; [@bib163]; [@bib160]), which reflects the activity of the HPA axis that is still developing ([@bib64]). The hypoactivity of this axis in response to stress is key during early life since it protects the developmental nervous system of stressful events ([@bib33]; [@bib54]; [@bib64]). If a stressor is able to raise the CORT and ACTH levels during SHRP it can cause multiple alterations in neurodevelopment ([@bib30]; [@bib39]), such as, a reduction in the density of GABAergic interneurons in the medial prefrontal cortex and the hippocampus ([@bib78]; [@bib12]), which have been linked to several neuropsychiatric disorders, such as schizophrenia, autism, and anxiety ([@bib70]).

Besides the possible protective role of AlloP for neonatal stress, it has to be considered that since alterations in neonatal AlloP levels have been related to several developmental disruptions, some of the detrimental effects of neonatal stress may be in part elicited by an alteration in neonatal NS levels. [@bib185] showed that both pups submitted to 6h per day of social isolation between postnatal days 2 and 6, and pups that were not socially isolated and that were administered AlloP (5 mg/kg) daily emitted fewer ultrasonic vocalizations than control rats during EMS at postnatal day 7. These authors proposed that the effects of social isolation on ultrasonic vocalizations could be mediated by an endogenous increase in AlloP; and therefore, administering it exogenously leads to the same effect ([@bib185]). Interestingly, when rats submitted to social isolation received a previous injection of AlloP, the rate of ultrasonic vocalizations was unaffected. This may again indicate a protective effect of AlloP against stress due to EMS when AlloP is administered prior to stress, as well as the endogenous AlloP increase that occurs as an adaptive response. In a set of experiments carried out in our laboratory we observed that early postnatal AlloP administration (from postnatal days 5--9) played a protective role against posterior effects of neonatal stress (maternal deprivation for 24 h at postnatal day 10). For instance, and consistent with previous works in adolescent ([@bib116]) and adult rats ([@bib157]), EMS increased locomotion and decreased exploration of holes in a new environment in adolescent age (postnatal day 40), and these effects were prevented by previous neonatal AlloP administration ([@bib111]). These data suggest that the previous increase in AlloP levels produced by administering it exogenously could alter the function of GABAA receptors, which in turn could interfere with the physiological response produced by EMS. However, the recorded anxiolytic effect of EMS measured in the elevated plus-maze test at adult age, which has also been reported by other authors who studied rats ([@bib34]; [@bib112]) and mice ([@bib68]), was not prevented or neutralized by administering AlloP previously to EMS ([@bib111]). Thus, it seems that the kind of behavior and the developmental period are key factors for obtaining the protective effects of AlloP on neonatal stress.

3. The effects of changes in neonatal allopregnanolone levels on {#sec3}
================================================================

3.1. Brain maturation {#sec3.1}
---------------------

As mentioned above, the brain in the fetal stage already acts as a steroidogenic organ ([@bib153]) and has NS levels similar to those found in the adult brain ([@bib101]). AlloP levels fluctuate during neurodevelopment, and are higher in fetal nervous tissue during late gestation ([@bib100]; [@bib86]). According to Hirst and his collaborators ([@bib90]), the high fetal levels of AlloP during late gestation would play a key role in regulating the activity of the fetal brain. In addition, stressful events during late pregnancy stimulate the release of AlloP; thus, this NS may play a neuroprotective role during pregnancy ([@bib33]; [@bib91]).

[@bib86] characterized AlloP pre and postnatal fluctuations in the frontal cortex of rats. These authors reported that fetuses have elevated AlloP levels during the last gestational days, which has been related to the mentioned protective role played by AlloP against gestational stress (see [@bib33] for review). These high levels decrease progressively during the first week of life, when rats have low levels similar to those found in the adult brain. Then, during the second week of life there is another rise in AlloP levels, and maximum values are reached between postnatal day 10 and 14, decreasing again to similar adult levels on postnatal day 15 and remaining low until puberty. This second peak in AlloP is time-related to the functional GABA shift from depolarization to hyperpolarization in both the neocortex and hippocampus (reviewed in [@bib55]). Unlike the adult brain, during early neurodevelopment, GABA has a depolarizing profile caused by the activation of GABAA to trigger Cl- ([@bib22], [@bib23]). The depolarization induced by GABA eliminates the voltage-dependent blockade exerted by magnesium in the NMDA-channel receptors, which generates a large influx of calcium and activates various neurotrophic mechanisms that mediate neuronal proliferation, migration and differentiation processes (see [@bib143] for a review). The depolarizing profile of GABA is promoted by the higher concentration of intracellular Cl-contained in immature neurons, since the sodium-potassium-chloride cotransporter type 1 (NKCC1), which transports Cl-within the cell, is expressed much more than the KCC2 potassium-chloride cotransporter (which extracts the Cl-out of the cell). This causes the intracellular accumulation of this anion. In contrast, an increase in KCC2 expression is observed to the detriment of NKCC1 in the adult brain, providing the hyperpolarizing profile of the GABAergic system ([@bib22], [@bib23]). Even so, it has to be kept in mind that this change in the response of the GABAA receptor depends on the age and sex of the subject, in addition to the area of the brain ([@bib22]). However, it has been observed in animal models that this change in GABAergic polarity would occur from the second postnatal week in several brain areas, such as the striatum and the spinal cord ([@bib56], [@bib55]) or the hippocampus ([@bib168]), and would be able to temporarily coincide with the increase in AlloP levels during postnatal day 10. In a previous work, we reported that the alteration of physiological AlloP levels by means of sub-chronic administration (from postnatal day 5--9) of AlloP or finasteride, which acts as an inhibitor of the 5α-reductase enzyme and decreases plasmatic AlloP levels in adult rats ([@bib3]; [@bib136]), alters the developmental expression of KCC2 in the hippocampus ([@bib127]). These results may indicate that AlloP participates in the GABA hyperpolarizing shift.

As discussed in the previous sections, NS can play an important role in regulating early neurodevelopment. Thus, when the endogenous NS levels are altered, for example, through the neonatal administration of AlloP, then the number and location of GABAergic interneurons in the adult prefrontal cortex are modified ([@bib85]), the total number of neurons in the dorsomedial nucleus of the thalamus decreases ([@bib83]) and the basal levels of striatal dopamine decrease ([@bib138]). The neonatal administration of progesterone, the main precursor of AlloP, also induces a decrease in basal dopamine levels, together with a decrease in serotonin levels in the striatum ([@bib137]). Furthermore, it has been documented that neonatal treatment with estradiol, which induces a persistent decrease in cerebral and plasma concentrations of progesterone and AlloP ([@bib122]; [@bib24]; [@bib37]), increases production of extracellular dopamine in the medial prefrontal cortex, an effect that can be reversed through subsequent treatment with progesterone ([@bib155]). However, the neonatal administration of the 5α-reductase inhibitor finasteride, which has been observed to tend to increase the AlloP levels in the neonatal hippocampus ([@bib129]; [@bib49]), causes an increase in the expression of the α4δ subunits of the GABAA receptor in this same structure ([@bib128]). This data set highlights the importance of basal levels of NS during early neurodevelopment because manipulating it alters the maturation of diverse brain structures.

3.2. Adolescent and adult behavior {#sec3.2}
----------------------------------

At the behavioral level, it has been observed that the manipulation of neonatal levels of NS such as AlloP, can modify adolescent and adult behavior. It has been shown that administrating AlloP during the early postnatal stage in rats causes a decrease in responses related to anxiety in the elevated plus-maze (EPM) in adult age, because animals spent more time and entered the open arms of the apparatus more often without showing differences in locomotor activity ([@bib185]; [@bib52]). It has also been shown that the early postnatal administration of AlloP causes a decrease in the anxiolytic effects of lorazepam in the EPM in adult animals, suggesting that an increase in neonatal levels of this NS could decrease sensitivity to the effects of this benzodiazepine ([@bib50]). However, it has been observed that the neonatal administration of finasteride causes a decrease in the time and number of entries in the open arms of the EPM in adult animals that have undergone stereotactic surgery ([@bib119]). Concerning the behavior induced by novelty, in our laboratory we have observed that neonatal treatment with finasteride can induce a decrease in hole exploration in the Boissier test during adolescence ([@bib51]). In contrast, a single administration of AlloP in the early postnatal stage can cause an increase in the exploratory behavior induced by a new environment in an open field (OF) in adulthood ([@bib50]). Regarding locomotor activity, other studies have shown that the neonatal administration of AlloP causes an increase in the activity induced by amphetamine during adulthood ([@bib84]). This suggests that this manipulation during the early postnatal period would increase the sensitivity to the stimulant effects of this drug. Our group has also conducted studies on prepulse inhibition (PPI). This is a pre-attentional task consisting of a weak stimulus (prepulse) preceding a stronger stimulus (pulse) that generates a startle reaction. Under normal conditions the prepulse produces an attenuation of the startle response reflex caused by the pulse. The neonatal administration of AlloP both injected acutely ([@bib84]), or during several consecutive days ([@bib51]; [@bib111]), has been observed to decrease PPI in adults. Altering the PPI has been linked to affecting the dopaminergic system and mesocortical and prefrontal cortex GABAergic systems ([@bib170]; [@bib84]) in addition to the dorsal and ventral hippocampus ([@bib182]). Thus, the behavioral results obtained in the PPI test are consistent with some of the structural alterations observed after the manipulation of neonatal NS levels (see section [3.1](#sec3.1){ref-type="sec"}).

Other studies have focused on observing behavioral effects in adverse situations, such as stress, after manipulating neonatal NS levels. As previously mentioned, acute stress increases the cerebral and plasma concentrations of AlloP in rodents ([@bib156]; [@bib7], [@bib8]; [@bib47]). This kind of response has also been observed in experimental studies in humans, since some types of stress, such as psychosocial stress, can increase circulating levels in healthy humans which do not present a lower basal AlloP concentrations ([@bib81]; [@bib62]; [@bib48]). In this way, it has to be kept in mind that the nature of the stressor may influence the magnitude of AlloP response in humans, as well as the moment when AlloP is sampled and because of interindividual characteristics. Moreover, periods of neurosteroid fluctuation, such as during the ovarian cycle, can influence that reactivity of AlloP in acute stress situations and it may be linked to alterations in the sensitivity of GABAA receptors to NS, resulting in mood instability in vulnerable women, such as those with premenstrual dysphoric disorder ([@bib48]). Interestingly, in our laboratory, we have observed that male wistar rats subjected to forced swimming during adulthood show an increase in plasma levels of AlloP, which are not observed if finasteride is previously administered ([@bib144]). One way to mimic the increase in AlloP levels observed after acute stress is by administering its precursor, progesterone ([@bib133]; [@bib152]). In this way, it has been previously reported that the administration of progesterone during early adolescence induces an anxiolytic-like behavior in the EPM regardless of previous neonatal NS levels manipulations ([@bib14]). Nevertheless, our group has documented that administering progesterone during adulthood causes an anxiogenic profile in EPM in those adult animals neonatally treated with finasteride ([@bib127]). Therefore, altering neonatal levels of NS by inhibiting the enzyme 5α-reductase may modify sensitivity to the anxiolytic effects caused by administering this AlloP precursor during adulthood. These differences between the results of both experiments could have been due to the stages of development (postnatal day 30 vs. postnatal day 90) in which progesterone was administered as well as the behavioral test was carried out. In this sense, we had already observed an effect of age on the behavioral evaluation, regardless of neonatal treatment, in our laboratory. Specifically, the hole exploration levels in the Boissier test were higher in postnatal day 40 than in postnatal day 60 ([@bib51]). These results show that the specific behavioral effects observed during a period of development do not necessarily have to manifest in other maturation stages ([@bib61]; [@bib9]; [@bib29]). However and as explained in section [2](#sec2){ref-type="sec"}, animals subjected to EMS stress had low exploration scores in the hole-board exploration test (Boissier test) during adolescence, which was neutralized or prevented by the neonatal administration of AlloP prior to separation ([@bib111]). In summary, quite a lot of evidence shows that manipulating neonatal levels of NS, such as AlloP, modifies the maturation of the nervous system at a structural and functional level, which is reflected at the behavioral level. A systematic review of the main studies modifying neonatal NS levels and the corresponding behavioral effects is presented in the [Table 1](#tbl1){ref-type="table"}.Table 1Effects of neonatal neuroactive steroid levels alteration on adult and adolescent behavior ([@bib1], [@bib17], [@bib31], [@bib60], [@bib98], [@bib105], [@bib108], [@bib113], [@bib139], [@bib167], [@bib176]).Abbreviations: PN, postnatal day; PN0, day of birth; s.c., subcutaneous injection; i.p., intraperitoneal injection; EMS, early maternal stress; PREGS, pregnenolone sulfate; THDOC, tetrahydrodeoxycorticosterone; EPM, elevated plus maze; OF, open field; PPI, prepulse inhibition; ORT, object recognition test; CPP, conditioned place preference; NOP, novel object preference.Table 1

4. Why to study the alteration of neonatal allopregnanolone and its possible effect on alcohol abuse vulnerability? {#sec4}
===================================================================================================================

First of all, it is important to highlight that if applying early postnatal stress can alter plasmatic and cerebral AlloP levels ([@bib79]; [@bib99]) (see section [3.1](#sec3.1){ref-type="sec"}), and neonatal stress has been considered to be a key factor that increases the vulnerability to developmental alterations and adult neuropsychiatric disorders (see [@bib4]; [@bib30]; [@bib39] for a review), it is reasonable to consider that early postnatal alterations in AlloP levels are an important factor to be considered for studying the development of behavioral disorders.

4.1. What has previously been observed at a behavioral level? {#sec4.1}
-------------------------------------------------------------

In relation to drug abuse, as mentioned above (see section [3.2](#sec3.2){ref-type="sec"}), altering early postnatal AlloP levels can affect novelty exploration and anxiety. Interestingly, an increase in novelty exploration has been related to a novelty or sensation seeking pattern, which has been linked to vulnerability to drug use and/or abuse ([@bib20]; [@bib59]; [@bib115]). It has been proposed that novelty seeking (tendency to explore new environments) and sensation seeking (tendency to search intense emotional experiences) are two related ([@bib2]; [@bib20]; [@bib18]) but dissociable traits ([@bib36]; [@bib19]; [@bib72]). Sensation seeking is usually inferred by measuring locomotor activity in a new environment ([@bib58]; [@bib150]), whereas novelty seeking is studied by determining the preference for new versus familiar environments using the conditioned place preference or the new object preference tests ([@bib18]; [@bib66]; [@bib146]; [@bib130]; [@bib57]). These two behavioral traits have been related to different aspects of drug abuse. It seems that a sensation seeking pattern could be related to the acquisition of drug intake ([@bib150]; [@bib103]; [@bib21]), whereas novelty seeking has proven to be important for drug abuse in addition to the severity of addiction behavior ([@bib187]; [@bib18]; [@bib72]; [@bib77]). A possible link between sensation/novelty seeking and drug use/abuse can be related to dopamine release in the nucleus accumbens. It has been documented that the animals who showed more locomotion in response to novelty also showed higher levels of mesolimbic dopamine release ([@bib71]; [@bib93]; [@bib117]), and similar results have been obtained in Roman High Avoidance rats ([@bib173]).

4.2. What has previously been observed at a neurochemical level? {#sec4.2}
----------------------------------------------------------------

It is important to note that early-postnatal manipulations of neuroactive steroid levels by administering progesterone, the main precursor of AlloP, affect the normal development and maturation of the dopaminergic meso-striatal systems ([@bib140]; [@bib137]). These results are similar to those previously reported in neonatally AlloP-treated rats ([@bib138]). It has been observed that the administration of progesterone increases cortical and plasmatic AlloP levels in animals ([@bib152]) as well as in the brain of progesterone-treated neonates ([@bib145]). The developing brains can synthesize AlloP from progesterone ([@bib153]) and, furthermore, the action of progesterone on many neuronal receptors, such as GABAA, seems to be mediated by its reduced metabolite AlloP ([@bib124]; [@bib165]). Thus, it is conceivable that at least part of the dopaminergic alterations observed in those progesterone-treated animals were induced by AlloP. Thus, if neonatal AlloP manipulation affects the maturation of dopamine systems, then it is conceivable that these animals have alterations in drug seeking behavior.

On the other hand, GABAA receptors participate in regulating excitability of the dopaminergic neurons in the ventral tegmental area ([@bib180]). Regarding this receptor, previous experiments carried out in our laboratory showed that early postnatal AlloP manipulation produced an over-expression of hippocampal GABAA receptors containing α4/δ subunits, and these changes were maintained in adult age ([@bib128]). This result is relevant for drug abuse vulnerability because this kind of GABAA receptor has been related to alcohol use. Several studies have shown that a low expression of α4/δ GABAA receptors in the mesolimbic system seems to be related to low alcohol consumption ([@bib125]; [@bib142]; [@bib159], [@bib158]).

4.3. The interaction between allopregnanolone levels and alcohol {#sec4.3}
----------------------------------------------------------------

Another important factor to take into consideration is that alcohol consumption or its administration (i.p.) increases brain cortical and hippocampal AlloP levels in adult animals ([@bib5]; [@bib175]; [@bib134], [@bib135]). Moreover, the development of tolerance to depressing alcohol effects has been linked to a reduction in AlloP production ([@bib96]; [@bib134]). Regarding human studies, although AlloP levels increase in the plasma of adolescent men and women after alcohol intoxication ([@bib171], [@bib172]), it has been observed that they don\'t increase or even decrease when the doses of alcohol consumption are moderate ([@bib92]) and/or when the subjects have reached adulthood ([@bib92]; [@bib151]). Thus, making a comparative study between different ages and alcohol consumption levels would be interesting.

In parallel, the systemic administration of AlloP leads to an increase in alcohol intake in rats that had low levels of basal consumption, and decreases alcohol ingestion in rats with high levels of alcohol consumption ([@bib95]; [@bib134]), even when AlloP was injected directly into the hippocampus ([@bib118]). In other brain structures, such as the ventral tegmental area, the over-expression of the steroidogenic enzyme cytochrome P450 side chain cleavage increased AlloP and reduced long-term operant ethanol self-administration in rats ([@bib45]). In mice, although differences in the two sexes have been detected, a dose-response relation has been proposed in several alcohol intake paradigms: low AlloP doses (3.2 mg/kg i.p.; 50 ng i.c.v.) increased EtOH ingestion, and high doses (17 or 24 mg/kg i.p.; 400 ng i.c.v.) decreased it ([@bib76], [@bib74], [@bib73], [@bib75]). These results suggest that changes in central AlloP production as a consequence of alcohol ingestion may be involved in some aspects of the alcohol abuse spectrum, such as the development of tolerance. Therefore, it has also been proposed that the anxiolytic effects of alcohol are, at least in part, mediated by the increase in central AlloP levels induced by the drug ([@bib89]).

In conclusion, taking these results together, it seems conceivable that alterations in AlloP levels during development can affect drug intake or drug seeking behaviors, and alcohol abuse is a reasonable study subject.

5. The effects of altering neonatal allopregnanolone levels on alcohol abuse {#sec5}
============================================================================

The developing brain shows a variety of neuroplasticity responses that are not normally shown in adult age. Several mechanisms contribute to the equilibrium between neuronal plasticity and homeostasis in the developing brain, which allow synaptic stability and flexibility ([@bib97]). Adverse events or pathological states can alter the normal homeostasis in the developing brain and induce an aberrant neuroplastic effect that can contribute to a neurophysiologic or behavioral abnormal phenotype ([@bib94]). Recent works carried out in our laboratory have shown that neonatal manipulation of AlloP levels by administering finasteride increased the consumption of a sweetened alcohol solution (10% EtOH + 3% glucose) in non-selected adult male rats ([@bib15]; [@bib109], [@bib110]). This increase in alcohol intake was reported in the initial period of consumption, specifically in a two-week procedure of EtOH access. Thus, it seems that early postnatal AlloP levels could be important for determining the initial sensitivity to alcohol seeking behavior in adulthood. Furthermore, when monoamine levels are analyzed in ventral striatum by means of HPLC, we observed that the neonatal finasteride group consumed a higher amount of alcohol and had lower levels of dopamine and serotonin in this brain structure compared to control groups when they were sacrificed at the end of the two-week consumption period ([@bib109]). Moreover, the levels of the main metabolites of dopamine (3,4-dihydroxyphenylacetic and homovanillic acid) and serotonin (5-hydroxyindoleacetic acid) were not affected. This indicates that animals neonatally treated with finasteride had an increased turnover ratio of dopamine and serotonin, which possibly indicates a decrease in dopaminergic and serotoninergic activities ([@bib109]). Interestingly, the effects of neonatal finasteride administration (postnatal days 5--9) on ethanol intake and ventrostriatal dopamine and serotonin levels described above were neutralized by later EMS (24 h of maternal separation at postnatal day 10) ([@bib109]). This last result suggests that in the same way that the effects of neonatal stress can be neutralized or prevented by the previous application of AlloP (see section [2](#sec2){ref-type="sec"}), the effects of an alteration in AlloP levels produced by finasteride administration can also be modulated by the posterior application of postnatal stress and the consequent increase in endogenous AlloP levels induced by it.

In a parallel experiment, we measured dopamine release in the nucleus accumbens during alcohol drinking in animals submitted to early postnatal manipulation of AlloP levels. Microdialysis results revealed that dopamine release in the nucleus accumbens (expressed as a baseline percentage), which was increased in controls after alcohol solution presentation, was not affected in neonatal finasteride treated animals ([@bib110]). Accordingly, the overall increase in dopamine release with respect to the baseline in response to solutions (ethanol and glucose) and food presentation was lower in finasteride subjects than in control subjects ([@bib110]). Taken together, the ventral striatum HPLC and nucleus accumbens microdialysis results seem to indicate a hypo-dopaminergic activity in early postnatal finasteride treated rats, which could be related to the increase in alcohol drinking reported in these animals.

In this way, it has been described that a hypo-dopaminergic activity, induced either by a decrease in dopamine D2 receptors or by a decreased presynaptic dopamine release in the striatum, leads to an excessive craving and seeking for substances known to cause dopamine release in nucleus accumbens ([@bib27], [@bib28]; [@bib174]). Several studies in rats have shown that lines selectively bred for high ethanol preference had a decreased dopamine D2 receptor density in the nucleus accumbens ([@bib121]), and lower dopaminergic innervation ([@bib38]; [@bib186]), with lower dopamine content in the nucleus accumbens ([@bib120]; [@bib141]). Similarly, alcohol addiction in humans has been related to significant reductions in D2 receptor availability as well as reduced dopamine release in the striatum (see [@bib177] for a review). Therefore, our data could indicate that the higher ethanol consumption in neonatal finasteride treated rats might be related to a blunted dopamine response in ventral striatum and nucleus accumbens.

Precisely, early postnatal finasteride administration decreased the locomotor activity induced by a low ethanol dose (0.5 g/kg), thus reducing the sensitivity to the stimulant motor effects of alcohol ([@bib14]). Reduced sensitivity to ethanol stimulating effects has been related to dopamine inhibition (see [@bib32] for a review). In accordance whit this, our results indicate that neonatally finasteride treated rats: (1) have lower dopamine levels in the ventral striatum and release in nucleus accumbens; (2) exhibit lower sensitivity to the motor stimulant effects of a low alcohol dose; and (3) show higher alcohol consumption in the two-week access procedure. Thus, following the hypo-dopaminergic hypothesis ([@bib27], [@bib26]; [@bib69]), it is reasonable to think that finasteride animals consumed greater amounts of ethanol in order to compensate the deficiency of mesolimbic dopamine; however, more experiments are needed to confirm this (see section [6](#sec6){ref-type="sec"}).

Moreover, in order to characterize the effects of early postnatal administration of finasteride on drug use/abuse behavior, we evaluated the novelty object preference, since the trait of novelty seeking has been related to both consumption and substance abuse ([@bib59], [@bib115]; [@bib18]) (see section [4](#sec4){ref-type="sec"}). The results indicated that animals neonatally treated with finasteride had a higher preference index for exploring the new object versus the familiar one ([@bib15]). Consequently, this increase in the preference for novelty could indicate that these subjects are more vulnerable to consuming addictive substances, which would be related to the increase in EtOH consumption exhibited by these animals. However, as we have already mentioned, in previous studies we have observed that animals neonatally treated with finasteride have low levels of both exploratory behavior and locomotor activity with respect to the control group ([@bib51]; [@bib129]). This suggests that the neonatal administration of finasteride can produce a novelty but not sensation seeking profile. This result would be in accordance with the hypothesis that proposes that these two traits are dissociable ([@bib36]; [@bib20]; [@bib72]). However, it would be interesting to carry out other behavioral tests in order to better define a profile of vulnerability (searching for sensations and/or novelty) together with evidence of drug use and abuse.

However, as we also observed decreased ventro-striatal levels of serotonin in the early postnatal finasteride treated rats, and serotonin together with dopamine has been proposed to modulate the motivational properties of alcohol ([@bib53]) and participate in alcohol abuse vulnerability ([@bib10]; [@bib181]). In addition, 5HT3 receptors could regulate the brain function and network formation during early development ([@bib65]). Thus, we initiated a set of experiments focusing on the serotoninergic system. Taking into account that AlloP, like the rest of neuroactive steroids, binds with high affinity to ionotropic receptors (for a review see [@bib161]), we decided to study possible alterations in the 5HT3 receptor function, the unique ionotropic subtype of serotonin receptors. Previous experiments have shown that AlloP at high doses negatively modulates 5HT3 receptors ([@bib179]), and it has also been described that mesolimbic dopamine release can be promoted by activating central 5HT3 receptors (for a review see [@bib11]). In a first experiment, we analyzed the effects of ondansetron on alcohol consumption (in the previously mentioned two-week free access procedure) in animals submitted to the manipulation of AlloP levels in the early postnatal period. Ondansetron is a 5HT3 antagonist that has been shown to effectively reduce alcohol intake in rats in free choice conditions, i.e., when the animals can choose between drinking a sweetened alcohol solution or drinking a sweetened control solution ([@bib88]; [@bib123]; [@bib164]). Although its efficacy varies depending on drinking conditions after stabilization of ethanol intake, no studies have focused on their possible effects in the initial period of ethanol intake (for instance the first two weeks of consumption), which is related to the initial alcohol seeking behavior. In our experiment, the highest dose of ondansetron (0.1 mg/kg) tested in male wistar rats decreased the consumption of alcohol, but only in the animals that were administered finasteride postnatally, which were the ones that consumed the highest amount of alcohol ([@bib15]). In control animals, the initial alcohol intake was not affected by ondansetron administration. As previously proposed, it seems that 5HT3 antagonists could be effective or ineffective depending on several variables such as the dose, the ethanol drinking conditions (initial versus stabilized), the duration of the treatment, or the sex or strain of the animals ([@bib123]; [@bib104]; [@bib132]; [@bib149]). Nevertheless, the fact that ondansetron was effective in our finasteride animals but not in controls suggests that 5HT3 receptors work differently in these animals as a consequence of the neonatal treatment, making them more sensitive to the effects of ondansetron. Thus, alterations in early postnatal serotoninergic pathways including 5HT3 receptors, together with those previously described that affect dopaminergic systems ([@bib140]; [@bib138]), could be related to the increase in ethanol intake in initial periods and the corresponding higher alcohol seeking behavior observed in the neonatal finasteride treated animals.

The results of the ondansetron experiment suggesting that 5HT3 receptors could be more sensitive to antagonists in neonatal finasteride animals, together with the possible role of these receptors in brain maturation, led us to study the expression of 5HT3 receptors in the early postnatal period. Therefore, we analyzed the density of 5HT3 receptors by means of Western Blot analyses in the midbrain of rats submitted to neonatal manipulation of AlloP. Preliminary results of our group ([@bib13]) indicate that early postnatal administration of either AlloP or finasteride alters the pattern of 5HT3 expression in male Wistar rat offspring. Specifically, neonatal AlloP administration anticipated the normal peak of 5HT3 expression (shown in controls) from postnatal day 12 to postnatal day 9, whereas the 5HT3 receptor densities in the finasteride treated group did not show statistical differences between the different days compared to control subjects. These results can be seen in [Fig. 1](#fig1){ref-type="fig"}.Fig. 1Percentage of 5HT3 protein receptor expression. **A)** 5-HT3 expression is different between PN6 and PN12 in control vehicle group (t = −2.73; p \< 0.05; the difference is indicated by the symbol: \*). Instead, 5-HT3 expression is different between PN6 and PN9 in Allopregnanolone group (t = −2.3; p \< 0.05; the difference is indicated by the symbol: **\#**). On the other hand, there were no statistically significant differences between the different days of samples extraction in Finasteride group. **B)** Western Blot images.Fig. 1

Therefore, these preliminary results seem to highlight the possible role played by serotonin systems containing 5HT3 receptors in the effects of early postnatal manipulation of AlloP levels on adult alcohol intake in initial periods of consumption, and thus on initial ethanol seeking behavior.

However, to our knowledge, there is very little information in the literature about the role of early postnatal manipulation of AlloP levels on the consumption or effects of the abuse of drugs other than alcohol. The only exception is a study that showed that AlloP administration at postnatal day 2 or 5 increased locomotor response to amphetamine (28% and 20% respectively) in adulthood (postnatal day 80) ([@bib84]). This suggests that possible variations in neonatal AlloP levels can be important for determining individual differences in the response to psycho-stimulant drugs, such as amphetamines, and the subsequent vulnerability to their abuse or addiction.

6. Perspectives {#sec6}
===============

Based on the above evidence it is clear that a set of new experiments are needed to determine the role of early postnatal neurosteroids, particularly AlloP, on drug seeking behavior and vulnerability to drug use or abuse in adult ages. For instance, it is very important to: (1) evaluate the effects of manipulating neonatal AlloP levels on chronic alcohol consumption, thus increasing the period of alcohol access; (2) have basal ventro-striatal DA/serotonin or accumbic DA levels previous to the alcohol access phase in order to establish causal relations; (3) analyze the different effects of ondansetron depending on neonatal manipulations in long-term stabilized alcohol consumption; (4) study 5HT3 expression in different brain structures and in different developmental stages (i.e. early postnatal, adolescent and adult ages); and (5) study the role that neonatal NS levels play in the vulnerability to abuse of drugs other than alcohol. Therefore, there is a long way to go to be able to accurately explain the role that AlloP plays during neurodevelopment in the vulnerability to drug abuse. These first exploratory experiments open the path towards designing new interesting studies. We have no doubt that this is a vast, but very exciting, field of research.

7. Conclusions {#sec7}
==============

At crucial stages of development, the physiological levels of NS, like AlloP, which fluctuate over a life-time in response to different physiological and environmental conditions, such as stress, seem to play an important role in the maturation of diverse areas of the brain as well as in the behavior related to these areas in different periods of life. Therefore, altering of early postnatal AlloP levels in the first weeks of life has been proven to affect the adult response to novel environmental stimuli, anxiety-like behaviors and the processing of sensory inputs. Moreover, recent studies indicate that early postnatal AlloP could play an important role in vulnerability to alcohol consumption. As evidence of this, it has been observed that inhibiting the enzyme 5α-reductase, which participates in AlloP synthesis, by administering finasteride in the early postnatal period: (1) increases initial alcohol consumption and the preference for novelty in adult age; (2) decreases the locomotor stimulant effects of low alcohol doses in adults; (3) promotes a hypo-dopaminergic profile in adulthood that is characterized by a decrease in dopamine levels in the ventral striatum and in dopamine release in the nucleus accumbens in response to alcohol and/or food presentation; and (4) increases the 5HT3 receptors' sensitivity to their antagonist ondansetron for reducing alcohol consumption, probably by altering early postnatal 5HT3 receptor expression. Thus, taken together, these results highlight the important role played by fluctuations in AlloP levels during the first two weeks of life for modulating adequate neurodevelopmental processes to prevent behavioral alterations related to neuropsychiatric and neurologic diseases.
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